+1-646-568-9980, +44-203-287-6050
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
immuno oncology IO market

Immuno Oncology (I-O) Market [By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types (Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma and Merkel Cell Carcinoma); By Region]: Market Size & Forecast, 2017 – 2025

Published: Jan 2018
Pages: 75
Format: PDF
Report ID: PM1083
License and Pricing
Buy Now Inquire Before Buying

Report Summary

The Global Immuno Oncology Market Size was estimated at USD 8,333.0 Million in 2017 and is expected to gain significant traction over coming years. The market is expected to grow at a CAGR of 21.5% for the forecast period from 2018-2025. Immuno-oncology, also known as cancer immunotherapy is a biologic treatment, which boosts the body's natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function. Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

North America Immuno Oncology (I-O) Market by Treatment Approaches, 2017 - 2025


Inside circle shows data for 2016 and outer circle shows data for 2025

The global immuno oncology market growth is majorly driven by the number of deaths arising owing to cancer is increasing every year and this has consequently enforced government organizations to take initiatives for the development of the health environments of individuals, by investing in R&D and enabling innovation with technological advancement so as to offer improved treatments. In addition, healthcare providers are concentrating on refining cancer therapies and decrease reappearance of cancer post-chemotherapy. This has pushed the growth of the immuno-oncology market globally.

The Immuno-Oncology market highlights started when the anti-CTLA-4 therapy i.e. Yervoy was launched by BMS IN 2013 but the most notable growth was observed when two of the therapies i.e. Pembrolizumab (Keytruda) by Merck and Nivolumab (Opdivo) by BMS targeting anti PD-1 therapies were launched for the treatment of melanoma cancer at the end of 2014. The rapid growth of these therapies and successful clinical results in several other oncology therapy areas has fuelled the overall growth of Immuno-Oncology market.

North America Immuno-Oncology (I-O) Market Size, By Treatment Approaches, 2017 - 2025
(USD Million)


The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The immuno oncology market report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

Segment Analysis

The global immuno-oncology market is segmented on the basis of treatment type, Novel Targets, by tumor type and region.

On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2017 that accounted for 54.7% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2017 with a total market share of 11.2%. on the basis of tumor type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2017 i.e. 15.31% among the listed tumor types in the report.

Polaris Market expects that the Immuno-Oncology therapies continues to be the improved and personalized treatment options for the cancer patients.

 The major segments which has been investigated in the global market from 2017-2025 are:

  • Market Analysis by Marketed Immuno-Oncology Therapies
  • Market Analysis by Companies
  • Market Analysis by Indications

The Marketed Therapies undertaken in forecast from 2017-2025 are:

  • Yervoy (Bristol Myers Squibb)
  • Keytruda (Merck)
  • Opdivo (Bristol Myers Squibb)
  • Tecentriq (Roche)
  • Bavencio (Merck/Pfizer)
  • Imfinzi (AstraZeneca)
  • Epacadostat (Incyte Pharmaceuticals)
  • Tremelimumab (AstraZeneca)

The Major Indications in Immuno-Oncology Therapies are:

  • Melanoma
  • Lung Cancer
  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Head & Neck Squamous Cell Carcinoma (HNSCC)
  • Renal Cell Cancer
  • Bladder Cancer

 Leading Companies investigated in the Report are

  • Bristol Myers Squibb
  • Merck
  • AstraZeneca
  • Roche
  • Pfizer
  • Incyte

Regional Analysis

North America was the largest regional market in 2017 with a market share of 30.4%. The regional market is expected to grow over the forecast period and account for 31.6% in 2025. Cancer patient count in the U.S. is among the top countries in the world. Moreover, the country has some of the world leading cancer institutions that constantly carry out technological developments in very frequent intervals. Development of immuno-oncology has been the works of some of the leading institutes in the region specifically the U.S. In addition, growing availability of drugs for this treatment process in the region along with the ability to afford such treatment cost of the people and presence of all the novel technological innovations with the equipment required are some of the major factors driving the regional market.


Key Take-Away